What is INIS's health score?

RADNOSTIX INC (INIS) has a TradeApes health score of 41 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is INIS's estimated fair value?

Based on our 5-year discounted cash flow model, RADNOSTIX INC's estimated fair value is $0.06 per share, representing a -14.4% downside from the current price. This is a model estimate, not a price target or investment recommendation.

Is INIS undervalued or overvalued?

Our model currently rates INIS as Fair Value. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for INIS... Refresh in a moment for the full analysis.

RADNOSTIX INC (INIS)

Healthcare Fair Value low weak

$0.07

Updated: 2026-06-06

TradeApes Score

Financial Strength

30 Weak

Operating Trend

40 Weak

Relative Value

40 Weak

Capital Allocation

55 Mixed

Risk

50 Mixed

Est. Fair Value $0.06

DCF Upside -14.4%

Sector Rank #3050 of 6566

Key Findings

+ Low leverage — net debt/EBITDA below 1×

Unlock Full Report →

− Weak interest coverage — earnings barely cover debt service

Unlock Full Report →

4 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.